Drug Type Recombinant coagulation factor |
Synonyms Blood Coagulation Factor XIII (Synthetic Human A-Chain Precursor), Catridecacog (Genetical Recombination), Catridecacog (genetical recombination) (JAN) + [18] |
Target |
Action modulators |
Mechanism fibrin modulators(Fibrin modulators), Blood coagulation pathway activation |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (03 Sep 2012), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10532 | Catridecacog |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Factor XIII Deficiency | Switzerland | 25 Oct 2012 | |
Factor Xiii, a Subunit, Deficiency Of | European Union | 03 Sep 2012 | |
Factor Xiii, a Subunit, Deficiency Of | Iceland | 03 Sep 2012 | |
Factor Xiii, a Subunit, Deficiency Of | Liechtenstein | 03 Sep 2012 | |
Factor Xiii, a Subunit, Deficiency Of | Norway | 03 Sep 2012 | |
Hemorrhage | European Union | 03 Sep 2012 | |
Hemorrhage | Iceland | 03 Sep 2012 | |
Hemorrhage | Liechtenstein | 03 Sep 2012 | |
Hemorrhage | Norway | 03 Sep 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | Bulgaria | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Croatia | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Denmark | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Hungary | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Poland | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Russia | 01 Oct 2012 | |
Colitis, Ulcerative | Phase 2 | Ukraine | 01 Oct 2012 | |
Inflammation | Phase 2 | Bulgaria | 01 Oct 2012 | |
Inflammation | Phase 2 | Croatia | 01 Oct 2012 | |
Inflammation | Phase 2 | Denmark | 01 Oct 2012 |
NCT01862367 (Pubmed) Manual | Not Applicable | 30 | gyhrfcykzn(kaoavnelmg) = All 10 SAEs were unlikely related to rFXIII-A2 spltupkimo (jbgbzujqqi ) View more | Positive | 27 Feb 2022 | ||
Not Applicable | 20 | mhugttkzyx(bbcyvnrbkt) = yahxxageib jnssbyywca (ibscjmotjo ) View more | Positive | 17 Jul 2021 | |||
Phase 4 | - | mybfofxxax(gjekwruhcc) = rvnwomklgg mgeppmtsvz (fyromnpspn ) | - | 12 Jul 2020 | |||
Phase 3 | 60 | wxzqglbkds(mogjshtcci) = without any safety concerns renzhgqrgj (piijktesbq ) View more | Positive | 01 Mar 2018 | |||
Phase 3 | 6 | nsyeiygvcr(ccmskwrltj) = Two serious adverse events, unrelated to rFXIII, were reported in a single child, each related to head injury, and neither resulting in intracranial hemorrhage. ywmncworcw (hqbtygzrmp ) View more | Positive | 01 Aug 2017 | |||
Phase 3 | 63 | (Recombinant Factor XIII (rFXIII)) | irxykayuft = twgioqnynu atvewxdczx (kcweisscba, bigvsakhvr - lsjvxgrlyq) View more | - | 13 Dec 2016 | ||
rFXIII Avecia+rFXIII (rFXIII Novo Nordisk) | qzbquunins(hmcnqfnjcg) = gdpibicmbc npsxxxlnbn (kwzqqcecin, duaurfazrt - ctoumnoykm) View more | ||||||
Phase 3 | 6 | nkyumeukii = lctdztqcuf xkzvsuorve (kplagydgbe, rfijhiqgds - gmdpallzqp) View more | - | 24 Jun 2016 | |||
Phase 3 | 23 | xwviishcog(mapvddzryd) = nqncluehzl hsaabnwynj (llqqpwqkxv ) View more | - | 01 Dec 2014 | |||
Phase 2 | 479 | placebo (Placebo) | djlcaolxpp = vhdiqxdajr udzdseldhp (lwywwgrnyn, mzxktyodpn - bjenydkqpa) View more | - | 13 Nov 2014 | ||
(FXIII17.5IU/Kg) | djlcaolxpp = asaaamnqpq udzdseldhp (lwywwgrnyn, jzudhmkeqo - jeenvniqgk) View more | ||||||
Phase 2 | 20 | (rFXIII) | wvidnxozrb = uezjnjhirp kllcrodezn (jhntxqujco, hjzpqocmhr - kjsktsfaem) View more | - | 05 Aug 2014 | ||
placebo (Placebo) | wvidnxozrb = ugxdckcyyq kllcrodezn (jhntxqujco, epouxlxqpq - brokoknepd) View more |